The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?-Reference-Cited by-同舟云学术

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?

Published:2023-06 Issue: Volume:Volume 14 Page:63-69
ISSN:1179-2728
Container-title:Lung Cancer: Targets and Therapy
language:en
Short-container-title:LCTT

Author:

Brazel Danielle,Ou Saihong Ignatius^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference34 articles.

1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

2. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

3. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

4. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

5. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC?;Lung Cancer: Targets and Therapy;2024-05

2. LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC;Lung Cancer: Targets and Therapy;2024-05

3. Advancements in NSCLC;American Journal of Clinical Oncology;2024-02-20